



## Original Article

## Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis

Kuan-Chieh Fang<sup>a</sup>, Yuan-Lung Cheng<sup>b,c</sup>, Chien-Wei Su<sup>a,c</sup>, Yuan-Jen Wang<sup>c,d</sup>,  
Keng-Hsin Lan<sup>a,c,e</sup>, Teh-Ia Huo<sup>a,e</sup>, Yi-Hsiang Huang<sup>a,f</sup>, Chi-Jen Chu<sup>a,c,\*</sup>, Chung-Chi Lin<sup>c,d</sup>,  
Ming-Chih Hou<sup>a,c,d</sup>, Han-Chieh Lin<sup>a,c</sup>, Fa-Yauh Lee<sup>a,c</sup>, Jaw-Ching Wu<sup>f,g</sup>, Shou-Dong Lee<sup>c,h</sup>

<sup>a</sup> Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

<sup>b</sup> Taipei Municipal Gan-Dau Hospital, Taipei, Taiwan, ROC

<sup>c</sup> Faculty of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, ROC

<sup>d</sup> Healthcare Center, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

<sup>e</sup> Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC

<sup>f</sup> Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC

<sup>g</sup> Division of Translational Research, Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

<sup>h</sup> Division of Gastroenterology, Department of Medicine, Cheng Hsin General Hospital, Taipei, Taiwan, ROC

Received April 11, 2016; accepted June 30, 2016

## Abstract

**Background:** Platelet count (PC) and fatty liver are both associated with metabolic syndrome (MS), obesity, and type 2 diabetes. While PC increases in obesity and type 2 diabetes, the severity of hepatic fibrosis caused by fatty liver reduces PC. We aimed to investigate the correlation of PC and MS in patients with and without fatty liver.

**Methods:** We enrolled consecutive patients who received health check-ups at Taipei Veterans General Hospital from 2002 to 2009. Ultrasonography was used to diagnose fatty liver, and MS was diagnosed according to the criteria defined by the International Diabetes Federation Task Force on Epidemiology and Prevention.

**Results:** Among the 29,797 patients, MS was present in 28.74%. Higher PC was correlated with MS using multivariate analysis, while fatty liver had the strongest association with MS. After dividing the patients by the presence or absence of fatty liver, higher PC was still associated with MS in both groups. The patients were further stratified by age and gender, and MS was correlated with PC among all age groups in women and in men under 60 years of age; however, the association between PC and MS did not reach statistical difference in men older than 60 years.

**Conclusion:** There is a significant correlation between PC and MS, and the correlation exists independent of gender, age, and fatty liver. PC may act as a surrogate marker for MS, and physicians should be concerned with the presence of MS among patients with high PC.

Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords:** body mass index; fatty liver disease; metabolic syndrome; platelet count; sonography

## 1. Introduction

Metabolic syndrome (MS) has several risk factors, including central obesity, dyslipidemia, raised blood pressure, and fasting glucose for cardiovascular disease and Type 2 diabetes mellitus.<sup>1,2</sup> Fatty liver disease used to be considered an incidental pathological finding in Type 2 diabetes and

Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.

\* Corresponding author. Dr. Chi-Jen Chu, Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, 201, Sec. 2, Shih-Pai Road, Taipei, 112, Taiwan, ROC.

E-mail address: [cjchu@vghtpe.gov.tw](mailto:cjchu@vghtpe.gov.tw) (C.-J. Chu).

<http://dx.doi.org/10.1016/j.jcma.2016.07.003>

1726-4901/Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: Fang K-C, et al., Higher platelet counts are associated with metabolic syndrome independent of fatty liver diagnosis, Journal of the Chinese Medical Association (2016), <http://dx.doi.org/10.1016/j.jcma.2016.07.003>

obesity; however, it is found to be strongly related with features of MS and even considered to be included in the definition of MS.<sup>3,4</sup>

Higher PC is associated with cardiovascular disease and vascular complications as a result of its role in inflammation and thrombosis; also, platelet activation is observed in people with diabetes, hypertriglyceridemia, and insulin resistance.<sup>5–9</sup> Diabetes, hypertriglyceridemia, and insulin resistance are strongly associated with MS, and previous studies have found that PC is also elevated in patients with MS after adjustment for age, gender, ethnicity, and total cholesterol.<sup>10,11</sup> On the contrary, decreased PC is observed when significant hepatic fibrosis develops in patients with fatty liver, especially in conditions of nonalcoholic steatohepatitis, which is another disease that is highly associated with MS.<sup>12,13</sup>

Although MS, PC, and fatty liver are closely related, the association between PC among patients with MS with or without fatty liver has not been clarified by comprehensive analyses. The present study therefore aimed to investigate the correlation of PC and MS in patients with and without fatty liver from a large-scale cohort in Taiwan.

## 2. Methods

### 2.1. Study population

From the years 2002 to 2009, a total of 34,346 consecutive patients received health check-ups in the Healthcare Center at the Taipei Veterans General Hospital.<sup>14–16</sup> After excluding patients with hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, and HBV/HCV dual infections, 29,797 patients were enrolled for the final analysis (Fig. 1). All of them received complete clinical evaluations, laboratory examinations, and abdominal sonography. Body mass index (BMI) was defined as body weight in kilograms divided by the square of body height in meters.

Three of the following five abnormal findings are required for a diagnosis of MS according to the joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention<sup>1</sup>: elevated waist circumference (WC, men  $\geq 90$  cm or women  $\geq 80$  cm), triglyceride (TG)  $\geq 150$  mg/dL, low high-density lipoprotein (HDL)–cholesterol (men  $< 40$  mg/dL or women  $< 50$  mg/dL), systolic blood pressure (BP)  $\geq 130$  mm Hg and/or diastolic BP  $\geq 85$  mm Hg, and fasting glucose  $\geq 100$  mg/dL. Ultrasonography was performed to diagnose fatty liver according to the practice guideline proposed by the American Gastroenterological Association.<sup>17</sup>

This study followed the standards of the Declaration of Helsinki and was approved by the Institutional Review Board of Taipei Veterans General Hospital. As the dataset used in this study consisted of de-identified data from a retrospective cohort, the requirement for written informed consent was waived.

### 2.2. Biochemical, hematology, and serological markers

Venous blood samples were collected after an overnight fast. Serum HBV surface antigen (HBsAg) was tested by a




Fig. 1. Flow chart of patients in the study.

radioimmunoassay (Abbott Laboratories, North Chicago, IL, USA), and antibodies to HCV were tested using a second-generation enzyme immunoassay (Abbott Laboratories). Serum biochemistry were measured with a Roche/Hitachi Modular Analytics System (Roche Diagnostics GmbH, Mannheim, Germany). Hematological analysis was performed using a Beckman Coulter LH 780 Hematology Blood Analyzer (Beckman Coulter, Miami, FL, USA).

### 2.3. Statistical analysis

The study cohort was first stratified by gender, and patients with fatty liver were selected for further analysis. PC was stratified by age to show association with MS in both men and women. Pearson  $\chi^2$  and Student *t* test analyses were performed to compare categorical and continuous variables with two samples, respectively. Variables with statistical significance ( $p < 0.05$ ) or approximate significance ( $p < 0.1$ ) in univariate analysis were further included in multivariate analysis using a logistic regression model with the forward stepwise selection procedure. A  $p$  value  $< 0.05$  was considered

Table 1  
Factors associated with male patients with and without metabolic syndrome.

	All (N = 16,098)	Metabolic syndrome (n = 6525)	Nonmetabolic syndrome (n = 9573)	p
BMI, kg/m <sup>2</sup> <sup>a</sup>	24.64 ± 3.38	26.1 ± 3.12	23.64 ± 3.19	<0.001
Age, (y) <sup>a</sup>	53.0 ± 13.7	55.1 ± 12.6	51.5 ± 14.2	<0.001
WC, cm <sup>a</sup>	87.5 ± 9.2	91.8 ± 8.1	84.5 ± 8.7	<0.001
SBP, mm Hg <sup>a</sup>	126.8 ± 17.1	133.6 ± 16.7	122.1 ± 15.9	<0.001
DBP, mm Hg <sup>a</sup>	79.6 ± 14.4	83.8 ± 16.3	76.6 ± 12.1	<0.001
Fasting glucose, mg/dL <sup>a</sup>	97.6 ± 26.8	108.9 ± 35.4	90.0 ± 14.6	<0.001
Cholesterol, mg/dL <sup>a</sup>	198.1 ± 36.3	201.2 ± 37.3	196.0 ± 35.4	<0.001
HDL, mg/dL <sup>a</sup>	47.9 ± 12.1	41.6 ± 9.7	52.2 ± 11.7	<0.001
LDL, mg/dL <sup>a</sup>	126.9 ± 32.2	128.0 ± 32.8	126.2 ± 31.7	0.001
TG, mg/dL <sup>a</sup>	150.1 ± 98.6	205.7 ± 117.6	112.2 ± 58.3	<0.001
AST, U/L <sup>a</sup>	24.1 ± 13.3	25.9 ± 17.3	22.8 ± 9.4	<0.001
ALT, U/L <sup>a</sup>	30.9 ± 24.2	36.1 ± 29.9	27.3 ± 18.6	<0.001
GGT, U/L <sup>a</sup>	29.8 ± 43.2	36.3 ± 55.4	25.4 ± 31.6	<0.001
Platelets, 1000/mm <sup>3</sup> <sup>a</sup>	241.1 ± 57.5	242.9 ± 59.9	239.9 ± 55.8	0.001
Fatty liver (Yes/no) (%)	8710/7388 (54.1/45.9)	4760/1765 (73.0/27.0)	3950/5623 (41.3/58.7)	<0.001

ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; DBP = diastolic blood pressure; GGT =  $\gamma$ -glutamyltransferase; HDL = high-density lipoprotein; LDL = low-density lipoprotein; SBP = systolic blood pressure; TG = triglyceride; WC = waist circumference.

<sup>a</sup> Data expressed as mean ± standard deviation.

to be statistically significant. All statistical analyses were performed with SPSS for Windows version 17.0 (SPSS, Chicago, IL, USA).

### 3. Results

#### 3.1. Patient characteristics stratified by gender and MS

The demographic data of male patients are summarized in Table 1. The mean age of the male population was 53.0 years, and 6525 (40.53%) had MS. Male patients with MS were older and had higher BMIs, alanine aminotransferase (ALT), aspartate aminotransferase (AST),  $\gamma$ -glutamyltransferase (GGT), fatty liver prevalence, and PC.

The demographic data of female patients are summarized in Table 2. The mean age of the female population was 51.3 years, and 2039 (14.88%) had MS. Similarly, female patients with MS were older and had higher BMI, ALT, AST, GGT, and PC. They also had a significantly higher rate of fatty liver compared with those without MS (75.3% vs. 25.8%,  $p < 0.001$ ).

#### 3.2. Factors associated with MS by multivariate analysis

Using multivariate analysis, the presence of fatty liver diagnosed by ultrasonography had the strongest association with MS in both men and women, with odds ratios of 2.205 (95% confidence interval 2.0–2.4) and 3.275 (95% confidence

Table 2  
Factors associated with female patients with and without metabolic syndrome.

	All (N = 13,699)	Metabolic syndrome (n = 2039)	Nonmetabolic syndrome (n = 11,660)	p
BMI, kg/m <sup>2</sup> <sup>a</sup>	22.85 ± 3.57	26.65 ± 3.84	22.19 ± 3.07	<0.001
Age, (y) <sup>a</sup>	51.3 ± 12.6	60.0 ± 11.1	49.8 ± 12.3	<0.001
WC, cm <sup>a</sup>	79.5 ± 9.8	90.5 ± 9.3	77.5 ± 8.5	<0.001
SBP, mm Hg <sup>a</sup>	121.3 ± 19.8	138.9 ± 18.4	118.2 ± 18.4	<0.001
DBP, mm Hg <sup>a</sup>	75.2 ± 13.7	83.4 ± 20.9	73.7 ± 11.4	<0.001
Fasting glucose, mg/dL <sup>a</sup>	93.0 ± 21.9	115.3 ± 34.4	89.2 ± 15.9	<0.001
Cholesterol, mg/dL <sup>a</sup>	200.5 ± 37.8	209.0 ± 39.9	199.0 ± 37.2	<0.001
HDL, mg/dL <sup>a</sup>	60.5 ± 15.2	47.1 ± 10.2	62.8 ± 14.8	<0.001
LDL, mg/dL <sup>a</sup>	123.4 ± 33.6	132.2 ± 34.7	121.9 ± 33.1	<0.001
TG, mg/dL <sup>a</sup>	107.3 ± 66.8	187.4 ± 88.0	93.3 ± 50.7	<0.001
AST, U/L <sup>a</sup>	21.8 ± 13.0	26.4 ± 20.6	21.0 ± 10.9	<0.001
ALT, U/L <sup>a</sup>	22.5 ± 18.5	31.8 ± 26.0	20.9 ± 16.3	<0.001
GGT, U/L <sup>a</sup>	18.8 ± 26.3	27.5 ± 31.9	17.3 ± 24.9	<0.001
Platelet, 1000/mm <sup>3</sup> <sup>a</sup>	260.1 ± 62.0	262.2 ± 66.2	259.7 ± 61.2	0.009
Fatty liver (yes/no) (%)	4545/9154 (33.2/66.8)	1535/504 (75.3/24.7)	3010/8650 (25.8/74.2)	<0.001

ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; DBP = diastolic blood pressure; GGT =  $\gamma$ -glutamyltransferase; HDL = high-density lipoprotein; LDL = low-density lipoprotein; SBP = systolic blood pressure; TG = triglyceride; WC = waist circumference.

<sup>a</sup> Data expressed as mean ± standard deviation.

Table 3  
Factors associated with metabolic syndrome by multivariate analysis.

	Odds ratio	95% confidence level	p
All patients			
Female			
BMI, per kg/m <sup>2</sup>	1.311	1.288–1.335	<0.001
Age, per year	1.065	1.059–1.071	<0.001
ALT, per U/L	1.007	1.004–1.009	<0.001
GGT, per U/L	1.004	1.002–1.005	<0.001
Platelets, per 1000/mm <sup>3</sup>	1.001	1.001–1.002	0.002
Fatty liver	3.275	2.888–3.714	<0.001
Male			
BMI, per kg/m <sup>2</sup>	1.242	1.225–1.259	<0.001
Age, per year	1.032	1.029–1.035	<0.001
ALT, per U/L	1.006	1.004–1.008	<0.001
GGT, per U/L	1.005	1.004–1.007	<0.001
Platelets, per 1000/mm <sup>3</sup>	1.002	1.001–1.002	<0.001
Fatty liver	2.205	2.040–2.384	<0.001
Patients with fatty liver			
Female			
BMI, per kg/m <sup>2</sup>	1.382	1.339–1.426	<0.001
Age, per year	1.080	1.070–1.089	<0.001
ALT, per U/L	1.010	1.005–1.015	<0.001
Platelets, per 1000/mm <sup>3</sup>	1.002	1.000–1.003	0.028
Male			
BMI, per kg/m <sup>2</sup>	1.351	1.320–1.383	<0.001
Age, per year	1.032	1.028–1.037	<0.001
ALT, per U/L	1.005	1.001–1.009	0.021
GGT, per U/L	1.005	1.003–1.007	<0.001
Platelets, per 1000/mm <sup>3</sup>	1.002	1.001–1.003	0.002
Patients without fatty liver			
Female			
BMI, per kg/m <sup>2</sup>	1.270	1.242–1.297	<0.001
Age, per year	1.054	1.046–1.061	<0.001
ALT, per U/L	1.006	1.003–1.009	<0.001
GGT, per U/L	1.005	1.002–1.007	0.001
Platelets, per 1000/mm <sup>3</sup>	1.001	1.000–1.002	0.027
Male			
BMI, per kg/m <sup>2</sup>	1.185	1.166–1.205	<0.001
Age, per year	1.031	1.027–1.036	<0.001
ALT, per U/L	1.007	1.005–1.009	<0.001
GGT, per U/L	1.005	1.004–1.007	<0.001
Platelets, per 1000/mm <sup>3</sup>	1.002	1.001–1.003	<0.001

ALT = alanine aminotransferase; BMI = body mass index; GGT =  $\gamma$ -glutamyltransferase.

interval 2.9–3.7), respectively. Older age and higher BMI, ALT, and GGT were correlated as well (Table 3 and Fig. 2A). Stratifying patients by age revealed that those with fatty liver had a higher rate of MS in all age groups (Fig. 2B). Further analysis disclosed that a higher serum ALT level was associated with MS in people with fatty liver disease and the association existed in all age groups as well (Fig. 2C and 2D).

### 3.3. J curve phenomenon occurred between PC and MS

The prevalence of MS was further analyzed after the male and female population was separated into 10 quantiles based on PC from 1 (the lowest PC group) to 10 (the highest PC group) (Fig. 3A and 3B). The result showed a J curve phenomenon in both genders, and the phenomenon was more prominent in men. The prevalence of fatty liver was also evaluated after the male and female population was divided to

10 quantiles by PC (Fig. 3C and 3D). No J curve phenomenon was noted between fatty liver disease and PC.

### 3.4. PC was associated with MS irrespective of fatty liver and age

As fatty liver was the most important determinant of MS in this study, we divided patients by fatty liver disease to further assess the impact of PC on MS. As shown in Table 3, higher PC was still an independent risk factor associated with MS in both genders irrespective of the status of fatty liver.

The prevalence of MS in each age group among men and women is documented in Table 4. With further analysis, higher PC was correlated with MS among all age groups in women and in men under 60 years of age (Fig. 4). The association between PC and MS did not reach statistical significance in men older than 60 years.

## 4. Discussion

Our large study demonstrated that PC was higher in MS patients, and, more importantly, the association existed after adjusting for age, gender, and the status of fatty liver.

The prevalence of MS is nearly 35% in the United States, according to a recent analysis of the population from 2003 to 2012.<sup>18</sup> While the prevalence of MS was approximately 12% between 1999 and 2002 in Taiwan, it was much higher in the current study (28%), which may have been because of westernization of diet, greater awareness of the syndrome, or higher socioeconomic status of the patients.<sup>19</sup>

Nonalcoholic fatty liver disease (NAFLD) is strongly associated with MS, which is demonstrated by the fact that approximately 90% of the patients with fatty liver have more than one feature of MS, and 33% of them have three or more. NAFLD has also been seen as the hepatic expression of MS.<sup>4</sup> The association between NAFLD and MS exists in not only obese and type 2 diabetes mellitus patients but also nonobese and nondiabetic individuals.<sup>20</sup> In concordance with previous published results, our current study showed that the prevalence of MS increased with age (Fig. 2B), and that fatty liver was the strongest association factor with MS in both genders (Table 3). Of note, people with fatty liver disease who had active hepatic necroinflammation and elevated serum ALT levels were correlated with an even higher rate of MS, and the association existed among all age groups (Fig. 2C and 2D).

Regarding the pathogenic role of mean platelet volume (MPV) and PC in the development of MS, growing evidence suggests that MPV should be regarded as a new inflammation marker and associated with the risk of cardiovascular disease, Type 2 diabetes, and MS.<sup>21</sup> Information with respect to MPV might not have been available in the current study because the data were obtained from routine health check-ups; however, a recently published study demonstrated a close association between MPV and PC.<sup>22</sup> According to published literature, more and larger reactive platelets develop in the presence of conditions such as obesity and endothelial dysfunction under the influence of growth factors and cytokines.<sup>23</sup> Additionally,




Fig. 2. Metabolic syndrome prevalence divided by (A) gender and fatty liver disease, (B) age and fatty liver disease, (C) gender and ALT among people with fatty liver (D) age and ALT among people with fatty liver. ALT = alanine aminotransferase.

platelets are associated with cardiovascular disease and vascular complications because of their role in inflammation and thrombosis. Stokes et al<sup>5–8</sup> mentioned that platelets deposited chemoattractants on the vessel wall and directly interact with leukocytes and the vessel wall through the mediation of factors, such as P-selectin, glycoprotein (GP)1a, GPIIb/IIIa, and CD40L.<sup>5–8</sup> Platelet activation has also been observed in people with Type 2 diabetes, hypertriglyceridemia, and insulin resistance through the decreased production of nitric oxide and increased oxidative stress.<sup>9</sup> Insulin resistance, obesity, and high triglyceride are the underlying factors for MS, and previous studies have found that PC is elevated in patients with MS after adjustment for age, gender, ethnicity, and total cholesterol.<sup>10,11,24–26</sup> The present study confirmed that PC was significantly associated with MS after adjustment for age, gender, and status of fatty liver (Table 3 and Fig. 4). Although other factors, such as age, BMI, and fatty liver, had higher odds ratios than PC had, multivariate analysis and stratified analysis confirmed that a higher PC was correlated with MS. It indicated that platelet activation might also play an important and independent role in MS. Further prospective studies are warranted to validate this phenomenon.

Different from our study results, a Korean study that enrolled 3827 patients showed that PC and MS were associated in women only.<sup>27</sup> The possible explanations for this

discrepancy were different population composition and a larger sample size compared with our current study. Also, our study showed that the association between PC and MS was less significant for participants above 60 years of age, especially in men. Older patients of each ethnicity consistently have lower PC than young adults, and the phenomenon may be explained by a survival advantage to having lower PC or diminished hematopoietic stem-cell reserve.<sup>28,29</sup> Accordingly, the linkage between PC and MS in elderly patients might be weakened, but the hypothesis needs to be further elucidated.

The role of PC in patients with fatty liver is intriguing. Obesity is characterized by chronic inflammation and associated with an increased risk of fatty liver, and insulin resistance is a universal finding in the disease.<sup>30,31</sup> Meanwhile, PC is independently associated with insulin resistance, and the decrease in PC observed in obesity patients after bariatric surgery may reflect decreased hepatic inflammation.<sup>32,33</sup> In contrast, a linear decrease of PC with increasing histological severity of hepatic fibrosis in fatty liver is noticed, especially in conditions of nonalcoholic steatohepatitis. PC is included in several noninvasive scores, which reveal a negative correlation with fibrotic levels in patients with fatty liver diseases.<sup>12,13</sup> While MS is related to PC and fatty liver, the relationship between PC among patients with MS with or without fatty liver was not clarified. Based on this study, we found that PC






Fig. 3. Metabolic syndrome prevalence in different quantiles based on PC in (A) women and (B) men. Fatty liver prevalence in different quantiles by PC in (C) women and (D) men. PC = platelet count.

was positively related with MS after adjustment for BMI, age, and gender. After dividing patients by the status of fatty liver, PC was still correlated with MS (Table 3).

Our study demonstrated a J curve phenomenon between PC and MS, which is consistent with the concept that extreme values of PC are related to cardiovascular diseases.<sup>34</sup> However, the phenomenon did not apply to the relationship between PC and fatty liver. The exact mechanism is not fully elucidated. However, previous studies showed that the grade of steatosis might reduce with the progression of hepatic fibrosis and reduced PC in patients with fatty liver disease.<sup>35</sup> It may explain the lower PC being paired with increased fibrosis and reduced steatosis.

The strengths of this study were the large sample size and detailed biochemical data, which provide robust evidence to elucidate the correlation between PC and MS. However, several limitations need to be addressed. First, our study

population had a high socioeconomic status, and could afford the expense of a physical check-up in a medical center. Whether the results of this study could represent the general population in Taiwan requires further studies to be validated. Second, alcohol consumption was not recorded and assessed. However, the prevalence of alcoholism was reported to be 1.5% in Taiwanese communities; therefore, it might have little influence on the result.<sup>36</sup> Third, PC can be influenced by other factors, including infection, medication, and hematological diseases. Given that the patients received physical check-ups in the hospital, the incidence of acute infection should be minimal. The incidence of drug-induced thrombocytopenia was also low, at about one or two cases per 100,000 per year. Primary hematological diseases account for <5% of patients with elevated PC.<sup>37,38</sup> These factors might have had only a little impact on the current study. Fourth, whether patients had diabetes mellitus, hypertension, or dyslipidemia was unknown

Table 4  
Metabolic syndrome prevalence in different age groups.

<b>Male</b>						
Age (y)	<30	30–40	40–50	50–60	60–70	≥70
People with metabolic syndrome (%)	106 (15.6)	561 (28.9)	1418 (39.5)	2265 (43.1)	1246 (48.7)	929 (45.0)
People without metabolic syndrome (%)	547 (84.4)	1382 (71.1)	2175 (60.5)	2991 (56.9)	1314 (51.3)	1137 (55.0)
<b>Female</b>						
Age (y)	<30	30–40	40–50	50–60	60–70	≥70
People with metabolic syndrome (%)	16 (2.3)	49 (2.8)	235 (7.3)	727 (15.2)	599 (27.6)	413 (37.5)
People without metabolic syndrome (%)	673 (97.7)	1719 (97.2)	2968 (92.7)	4043 (84.8)	1568 (72.4)	689 (62.5)




Fig. 4. Platelet count in different age groups stratified by metabolic syndrome in (A) men and (B) women.

and whether they took medication to control these diseases was not documented, either. Fifth, the gold standard for the diagnosis of fatty liver is liver biopsy. However, the invasiveness of that procedure means that it is not feasible for the general population. The lack of biopsy results also prevented us from further analyzing the influence of fibrosis severity. In the present study, the diagnosis of fatty liver was made by ultrasonography and defined by at least two of three abnormal findings: diffusely increased echogenic liver greater than kidney or spleen, vascular blurring, and deep attenuation of ultrasound signal with a sensitivity of 89% and specificity of 93%.<sup>39,40</sup>

In conclusion, the present study indicated a significant correlation between PC and MS, and the association existed independent of gender, age, and status of fatty liver. PC may act as a surrogate marker for MS, and physicians should be concerned with the presence of MS among patients with high PC.

## Acknowledgments

This study was supported by grants from the National Science Council (NSC 101-2314-B-075-014, NSC 104-2314-B-075-076) and Taipei Veterans General Hospital (V102C-151). All authors approved the final version of the article, including the authorship list.

## References

- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640–5.
- Cheng YL, Wang YC, Lan KH, Huo TI, Huang YH, Su CW, et al. Anti-hepatitis C virus seropositivity is not associated with metabolic syndrome irrespective of age, gender and fibrosis. *Ann Hepatol* 2015;14:181–9.

3. Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G, et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. *Diabetes Care* 2008; **31**:562–8.
4. Almeda-Valdes P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. *Ann Hepatol* 2009; **8**(Suppl 1):S18–24.
5. Li N, Hu H, Lindqvist M, Wikstrom-Jonsson E, Goodall AH, Hjendahl P. Platelet-leukocyte cross talk in whole blood. *Arterioscler Thromb Vasc Biol* 2000; **20**:2702–8.
6. Turakhia MP, Murphy SA, Pinto TL, Antman EM, Giugliano RP, Cannon CP, et al. Association of PC with residual thrombus in the myocardial infarct-related coronary artery among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. *Am J Cardiol* 2004; **94**:1406–10.
7. Cho NH, Becker DJ, Ellis D, Kuller LH, Drash AL, Orchard TJ. Spontaneous whole blood platelet aggregation, hematological variables and complications in insulin-dependent diabetes mellitus: the Pittsburgh Epidemiology of Diabetes Complications Study. *J Diabetes Complications* 1992; **6**:12–8.
8. Stokes KY, Granger DN. Platelets: a critical link between inflammation and microvascular dysfunction. *J Physiol* 2012; **590**:1023–34.
9. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. *Diabetes Care* 2009; **32**:525–7.
10. Zaccardi F, Rocca B, Pitocco D, Tanese L, Rizzi A, Ghirlanda G. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. *Diabetes Metab Res Rev* 2015; **31**:402–10.
11. Jesri A, Okonofua EC, Egan BM. Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. *J Clin Hypertens (Greenwich)* 2005; **7**:705–11.
12. Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, et al. PC for predicting fibrosis in nonalcoholic fatty liver disease. *J Gastroenterol* 2011; **46**:1300–6.
13. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. *J Hepatol* 2013; **58**:1007–19.
14. Wu WC, Wu CY, Wang YJ, Hung HH, Yang HI, Kao WY, et al. Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34346 subjects. *Aliment Pharmacol Ther* 2012; **36**:560–8.
15. Yang BL, Wu WC, Fang KC, Wang YC, Huo TI, Huang YH, et al. External validation of fatty liver index for identifying ultrasonographic fatty liver in a large-scale cross-sectional study in Taiwan. *PLoS ONE* 2015; **10**:e0120443.
16. Cheng YL, Wang YJ, Kao WY, Chen PH, Huo TI, Huang YH, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. *PLoS ONE* 2013; **8**:e72049.
17. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012; **142**:1592–609.
18. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. *JAMA* 2015; **313**:1973–4.
19. Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, Huang CC, et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). *Int J Obes* 2006; **30**:794–9.
20. Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. *Arch Intern Med* 2004; **164**:2169–75.
21. Farah R, Khamisy-Farah R. Significance of MPV, RDW with the presence and severity of metabolic syndrome. *Exp Clin Endocrinol Diabetes* 2015; **123**:567–70.
22. Mastellos N, Andreasson A, Huckvale K, Larsen M, Curcin V, Car J, et al. A cluster randomised controlled trial evaluating the effectiveness of eHealth-supported patient recruitment in primary care research: the TRANSFoRm study protocol. *Implement Sci* 2015; **10**:15.
23. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. *Int J Clin Pract* 2009; **63**:1509–15.
24. Nakatochi M, Ushida Y, Yasuda Y, Yoshida Y, Kawai S, Kato R, et al. Identification of an interaction between VWF rs7965413 and PCAs as a novel risk marker for metabolic syndrome: an extensive search of candidate polymorphisms in a case-control study. *PLoS ONE* 2015; **10**:e0117591.
25. Lim HJ, Seo MS, Shim JY, Kim KE, Shin YH, Lee YJ. The association between PC and metabolic syndrome in children and adolescents. *Platelets* 2015; **26**:758–63.
26. Chen YL, Hung YJ, He CT, Lee CH, Hsiao FC, Pei D, et al. PC can predict metabolic syndrome in older women. *Platelets* 2015; **26**:31–7.
27. Park BJ, Shim JY, Lee HR, Jung DH, Lee JH, Lee YJ. The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. *Platelets* 2012; **23**:45–50.
28. Segal JB, Moliterno AR. PCs differ by sex, ethnicity, and age in the United States. *Ann Epidemiol* 2006; **16**:123–30.
29. Biino G, Santimone I, Minelli C, Sorice R, Frongia B, Traglia M, et al. Age- and sex-related variations in PC in Italy: a proposal of reference ranges based on 40987 subjects' data. *PLoS ONE* 2013; **8**:e54289.
30. Fabbri E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* 2010; **51**:679–89.
31. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. *J Clin Endocrinol Metab* 2006; **91**:4753–61.
32. Johansson HE, Haenni A, Zethelius B. PCs and liver enzymes after bariatric surgery. *J Obes* 2013; **2013**:567984.
33. Samocha-Bonet D, Justo D, Rogowski O, Saar N, Abu-Abeid S, Shenkerman G, et al. PCs and platelet activation markers in obese subjects. *Mediators Inflamm* 2008; **2008**:834153.
34. Gregg D, Goldschmidt-Clermont PJ. Cardiology patient page. Platelets and cardiovascular disease. *Circulation* 2003; **108**:e88–90.
35. Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. *Hepatology* 2010; **51**:1961–71.
36. Huang MC, Chen CC. Alcohol dependence in Taiwan: from epidemiology to biomedicine. *J Exp Clin Med* 2012; **4**:108–12.
37. Aydogan T, Kanbay M, Alici O, Kosar A. Incidence and etiology of thrombocytosis in an adult Turkish population. *Platelets* 2006; **17**:328–31.
38. Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. *Blood* 2010; **116**:2127–33.
39. Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. *Clin Radiol* 1991; **43**:26–31.
40. Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. *Hepatology* 2009; **50**:1403–11.